Vasudev Bailey

He has led investments for the firm in Freenome and Climax Foods. He is the founder of the ARTIS Ventures Healthcare Pioneers, which brings together some of the world’s brightest minds to accelerate and incubate life-changing ideas in healthcare. In his past role as Venture Partner at ARTIS, he helped portfolio companies with their business development and growth strategy. Prior to ARTIS, Vasudev co-founded and served as the general manager of the GLG Institute --the world’s largest network of CEOs and CXOs. Here, he worked with C-suite executives from Pfizer, AstraZeneca, Teva, McDonald’s, and others to build a forum to connect retired executives with aspiring leaders. He previously served as a consultant at McKinsey & Company, Vasudev received his PhD in Biomedical Engineering (the use of nanotechnology and epigenetics for personalized chemotherapy and early cancer detection), from the Johns Hopkins School of Medicine where he was recognized as both a Siebel and a Medtronic Scholar and member of Sigma Xi. He graduated magna cum laude and phi beta kappa from UC Irvine with a degree in biomedical engineering, and was both a Regents Scholar, Hodson Foundation fellow, Whitaker Foundation Fellow, and Henri Samueli Endowed Scholar. Vasudev has published over 30+ scientific papers/abstracts and holds four provisional patents from his research in nanotechnology for the early detection of cancer. He later broadened the technology for advancing personalized chemotherapy. He has been recognized as one of the world’s leading biomedical engineers by the Siebel Foundation. He has spoken on the topic of biotech, healthcare, and entrepreneurism at events including DTx West, Health 2.0, GIANT Health, Johns Hopkins Research Symposium on Engineering in Healthcare, AWIS Summit, and East/West CEO, and has been a distinguished guest lecturer at UC Irvine, Johns Hopkins and UCL. He has been quoted as an expert on biotech and healthcare in CNBC, Venture Capital Journal, HIT Consultant, Startupedia, International Business Times and more.